Soaring Demand Set to Propel Biologics Contract Development Market to $13.08 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Biologics Contract Development Market Through 2025?
The sphere of contract development for biologics has experienced swift expansion lately; its valuation is projected to ascend from $7.75 billion in 2024 to $8.55 billion the following year, reflecting a compound annual growth rate of 10.3%, a surge fueled by the broader expansion of the biologics sector, the increasing prominence of biopharmaceuticals, the inherent intricacy associated with biologics, the expiration of patents, and the drive for cost-effectiveness.

What's the Projected Size of the Global Biologics Contract Development Market by 2029?
The market encompassing contract development for biologics is projected to experience swift expansion over the forthcoming years, reaching a substantial valuation of $13.08 billion by 2029, fueled by an anticipated compound annual growth rate (CAGR) of 11.2%; this upward trajectory anticipated during the forecast window is largely traceable to advancements in digitalization and data analytics, enhanced risk management protocols, inherent flexibility and adaptability, a surge in research and development investments, and the increasing focus on precision medicine and bespoke therapeutic approaches, while prevailing significant currents shaping this market presently encompass regenerative medicine developments, the implementation of robust risk mitigation tactics, increased international partnerships, the adoption of cutting-edge technologies, and greater technological interconnectivity across operations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Top Growth Drivers in the Biologics Contract Development Industry: What's Accelerating the Market?
The escalating frequency of long-term illnesses, defined as conditions persisting for a year or more necessitating continuous healthcare, is anticipated to boost the market for biologics contract development in the foreseeable future. This surge in chronic ailment occurrences is concurrently escalating the need for the creation of innovative pharmaceuticals, such as biologics, which directly fuels the expansion of the biologics contract development sector. As an illustration, publicly available data from the UK's Office for Health Improvement & Disparities indicated that during the initial six months of 2023, there were 3,940 excess fatalities linked to chronic lower respiratory conditions, representing a 30 percent jump above projections; by the close of the year, this figure had reached 5,363, signifying a cumulative 22 percent rise overall, thereby establishing rising chronic disease rates as a key growth determinant for the biologics contract development market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

What Trends Will Shape the Biologics Contract Development Market Through 2029 and Beyond?
Within the biologics contract development sphere, technological leaps are gathering momentum, prompting principal entities in this sector to incorporate sophisticated innovations to solidify their market standing. A prime illustration of this trend is Lonza, a firm concentrating on contract manufacturing and development solutions situated in Switzerland, which introduced its bYlok technology platform in January 2022 specifically for the creation and production of bispecific antibodies. This novel platform effectively addresses the complication of incorrect light-heavy chain pairings, achieving manufacturing yields exceeding 95 percent in accuracy while retaining a format comparable to monoclonal antibodies, and it is made available to both pharmaceutical and biotechnology corporations via a straightforward research licensing agreement.

What Are the Main Segments in the Biologics Contract Development Market?
The biologics contract developmentmarket covered in this report is segmented -

1) By Source: Microbial; Mammalian; Others Sources
2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications
3) By Product Service: Cell Line Development; Process Development; Others Product Services

Subsegments:
1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources
2) By Mammalian: Chinese Hamster ovary* (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells
3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

Which Top Companies are Driving Growth in the Biologics Contract Development Market?
Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi

Which Regions Will Dominate the Biologics Contract Development Market Through 2029?
North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8219

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.